Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2014; 20(24): 7544-7554
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7544
Hepatitis C virus associated glomerulopathies
Abdullah Ozkok, Alaattin Yildiz
Abdullah Ozkok, Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul 34730, Turkey
Alaattin Yildiz, Division of Nephrology, Department of Internal Medicine, Istanbul School of Medicine, Istanbul University, Istanbul 34093, Turkey
Author contributions: Ozkok A searched the literature, gathered the information, and wrote the paper; Yildiz A designed and wrote the paper.
Correspondence to: Alaattin Yildiz, MD, Division of Nephrology, Department of Internal Medicine, Istanbul School of Medicine, Istanbul University, Capa, Topkapi, Istanbul 34093, Turkey. alayildiz@yahoo.com
Telephone: +90-542-2427320 Fax: +90-212-4142022
Received: October 24, 2013
Revised: February 8, 2014
Accepted: April 1, 2014
Published online: June 28, 2014
Abstract

Hepatitis C virus (HCV) infection is a systemic disorder which is often associated with a number of extrahepatic manifestations including glomerulopathies. Patients with HCV infection were found to have a higher risk of end-stage renal disease. HCV positivity has also been linked to lower graft and patient survivals after kidney transplantation. Various histological types of renal diseases are reported in association with HCV infection including membranoproliferative glomerulonephritis (MPGN), membranous nephropathy, focal segmental glomerulosclerosis, fibrillary glomerulonephritis, immunotactoid glomerulopathy, IgA nephropathy, renal thrombotic microangiopathy, vasculitic renal involvement and interstitial nephritis. The most common type of HCV associated glomerulopathy is type I MPGN associated with type II mixed cryoglobulinemia. Clinically, typical renal manifestations in HCV-infected patients include proteinuria, microscopic hematuria, hypertension, acute nephritis and nephrotic syndrome. Three approaches may be suggested for the treatment of HCV-associated glomerulopathies and cryoglobulinemic renal disease: (1) antiviral therapy to prevent the further direct damage of HCV on kidneys and synthesis of immune-complexes; (2) B-cell depletion therapy to prevent formation of immune-complexes and cryoglobulins; and (3) nonspecific immunosuppressive therapy targeting inflammatory cells to prevent the synthesis of immune-complexes and to treat cryoglobulin associated vasculitis. In patients with moderate proteinuria and stable renal functions, anti-HCV therapy is advised to be started as pegylated interferon-α plus ribavirin. However in patients with nephrotic-range proteinuria and/or progressive kidney injury and other serious extra-renal manifestations, immunosuppressive therapy with cyclophosphamide, rituximab, steroid pulses and plasmapheresis should be administrated.

Keywords: Hepatitis C virus infection, Glomerulopathy, Membranoproliferative glomerulonephritis, Cryoglobulinemia, Kidney transplantation, Membranous nephropathy, Diabetic nephropathy, IgA nephropathy, Focal segmental glomerulonephritis

Core tip: Hepatitis C virus (HCV) infection is found to be frequently associated with proteinuria, various glomerulopathies and higher risk of end-stage renal disease. HCV positivity has been linked to decreased graft and patient survivals after kidney transplantation. Treatment of HCV infection is a great clinical challenge in kidney transplant patients and in patients with diminished kidney function. In this review, we aimed to review kidney involvement in the course of HCV infection and treatment of HCV-associated glomerulopathies.